US 12636378 B2 / May 26, 2026

Targeted antigen delivery system and uses thereof

Disclosed are antigen delivery systems comprising a nanoparticle, wherein the nanoparticle is surface-modified with a cancer-specific cell targeting peptide and comprises an immunogenic HLA class I restricted peptide, wherein the HLA class I restricted peptide is a vaccine-dependent, immunogenic HLA class I restricted peptide; methods of treating a subject having cancer comprising administering said delivery systems; methods of killing cancer cells comprising contacting cancer cells delivery systems, wherein upon entry of the liposome into the cancer cells, the cancer cells present said peptide from said delivery system, wherein the cancer cells generate an immune response said peptide, and wherein the immune response to said peptide targets and kills the cancer cells presenting the vaccine-dependent, peptide; methods of generating a non-cancer secondary immune response that targets cancer cells comprising administering said delivery systems to a subject having cancer cells.

Publication details

Recorded assignee
SRI International
Publication number
US 12636378 B2
Publication type
Utility patent grant
Publication date
May 26, 2026
Filing date
Sep 21, 2021
CPC classes
A61K47/6911, C07K7/08, A61K39/12, A61K39/145, A61P35/00, A61P37/04, C07K14/005, C07K14/11, A61K38/00, A61K2039/55555, A61K2039/585, C12N2710/24122, C12N2710/24134, C12N2760/18422, C12N2760/18434
Inventors
Brown; Kathlynn C., McGuire; Michael J., Venugopal; Indu

Party names reflect the published document. Current ownership and legal status can change.

View patent publication →

Your defense tech briefing

Security verification will run before you submit.